Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markman

Showing results (351-360 of 1,623) with videos related to

Pageof 163
Sort By:
Gynecologic Oncology|September 10, 2002
The prophylactic administration of recombinant erythropoietin in the management of ovarian cancer: time for a definitive phase 3 randomized trialMaurie Markman
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1988
Supportive careM Markman
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1987
Supportive careM Markman
Oncology (Williston Park, N.Y.)|March 1, 1987
Current status of intracavitary chemotherapyM Markman
Journal of Women'S Health (2002)|February 15, 2019
Cancer in WomenMaurie Markman
Case Reports in Oncology|March 14, 2012
Involvement of bone in epithelial ovarian cancer: case report of an uncommon late metastatic eventMaurie Markman
Oncology|September 7, 2011
Use of predictive markers in oncology: are phase 3 trials always required?Maurie Markman
Minerva Ginecologica|June 10, 2011
Role of chemotherapy in epithelial ovarian cancerM Markman
Oncology|November 2, 2011
Patterns of care studies in oncology: considerable potential utility, but risk of serious biasMaurie Markman
Oncology|October 26, 2011
Outcomes when cancer treatment is delivered on, or off, a clinical trial: implications for generalizability of study resultsMaurie Markman
Pageof 163

Showing results (351-360 of 1,623) with videos related to

Sort By:
Pageof 163
Gynecologic Oncology|September 10, 2002
The prophylactic administration of recombinant erythropoietin in the management of ovarian cancer: time for a definitive phase 3 randomized trialMaurie Markman
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1988
Supportive careM Markman
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1987
Supportive careM Markman
Oncology (Williston Park, N.Y.)|March 1, 1987
Current status of intracavitary chemotherapyM Markman
Journal of Women'S Health (2002)|February 15, 2019
Cancer in WomenMaurie Markman
Case Reports in Oncology|March 14, 2012
Involvement of bone in epithelial ovarian cancer: case report of an uncommon late metastatic eventMaurie Markman
Oncology|September 7, 2011
Use of predictive markers in oncology: are phase 3 trials always required?Maurie Markman
Minerva Ginecologica|June 10, 2011
Role of chemotherapy in epithelial ovarian cancerM Markman
Oncology|November 2, 2011
Patterns of care studies in oncology: considerable potential utility, but risk of serious biasMaurie Markman
Oncology|October 26, 2011
Outcomes when cancer treatment is delivered on, or off, a clinical trial: implications for generalizability of study resultsMaurie Markman
Pageof 163